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Anti-folate receptor-α IgE but not IgG recruits macrophages to attack tumors  
via TNF-α/MCP-1 signaling 
Running Title: IgE activates macrophages against cancer via TNFα and MCP-1 
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Abstract 
 
IgE antibodies are key mediators of anti-parasitic immune responses, but their potential for 
cancer treatment via antibody-directed cell-mediated cytotoxicity (ADCC) has been little 
studied. Recently, tumor antigen-specific IgEs were reported to restrict cancer cell growth by 
engaging high-affinity Fc receptors on monocytes and macrophages, however, the underlying 
therapeutic mechanisms were undefined and in vivo proof-of-concept was limited. Here, an 
immunocompetent rat model was designed to recapitulate the human IgE-Fcε receptor system for 
cancer studies. We also generated rat IgE and IgG monoclonal antibodies specific for the folate 
receptor (FRα), which is expressed widely on human ovarian tumors, along with a syngeneic rat 
tumor model expressing human FRα. Compared with IgG, anti-FRα IgE reduced lung 
metastases. This effect was associated with increased intra-tumoral infiltration by TNFα+ and 
CD80+ macrophages plus elevated TNFα and the macrophage chemoattractant MCP-1 in lung 
bronchoalveolar lavage fluid. Increased levels of TNFα and MCP-1 correlated with IgE-
mediated tumor cytotoxicity by human monocytes and and with longer patient survival in 
clinical specimens of ovarian cancer. Monocytes responded to IgE but not IgG exposure by 
upregulating TNFα, which in turn induced MCP-1 production by monocytes and tumor cells to 
promote a monocyte chemotactic response. Conversely, blocking TNFα receptor signaling 
abrogated induction of MCP-1, implicating it in the antitumor effects of IgE. Overall, these 
findings show how anti-tumor IgE reprograms monocytes and macrophages in the tumor 
microenvironment, encouraging the clinical use of IgE antibody technology to attack cancer 
beyond the present exclusive reliance on IgG. 
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Introduction 
 
Engagement of tumor-specific monoclonal antibodies via their Fc receptors contributes 
significantly to the anti-tumor effects of the immune system (1). Focusing effector cells such as 
monocytes/macrophages and natural killer (NK) cells against cancer-associated components may 
contribute to the functions of therapeutic antibodies such as trastuzumab, cetuximab and the 
checkpoint inhibitor ipilimumab (2, 3). Antibody engineering strategies to optimize antibody-
effector cell interactions and to direct these cells against tumors, may therefore improve 
therapeutic efficacy (4, 5). 
One strategy to influence these interactions is the exploration of changes to the structure of 
antibody Fc regions. The IgE immunoglobulin class is characterized by high affinity for cognate 
interaction with Fcε receptors (100-10,000 times higher than that of IgG for FcγR) on distinct, 
often tumor-resident, effector cells such as monocytes/macrophages (6, 7). Although IgE 
antibodies play pathogenic roles in allergic inflammation by triggering mast cell degranulation 
and promoting eosinophil inflammation, they also contribute to the host immune defense against 
parasitic infections. The potential of IgE to induce inflammatory responses at tumor sites may be 
harnessed through IgE receptor-expressing effector cells such as monocytes and macrophages in 
tumors. Strategies to implement this approach include recombinant tumor-associated antigen 
(TAA)-specific IgEs, and active immunotherapy triggering adaptive IgE responses against 
cancer (8-12).  
Folate receptor alpha (FRα) is overexpressed by several solid tumors, most significantly by 
epithelial ovarian carcinomas (13), and is a desirable target for TAA-specific IgE due to 
overexpression in tumors, and no/low expression and restricted distribution in normal tissues. 
Additionally, evidence of negative associations between allergies and reduced risk of 
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gynaecological malignancies is reported (14), while little is known about IgE immunity against 
ovarian carcinoma antigens in patients (15). The chimeric (mouse V/human C) IgE antibody 
hMOv18 IgE, specific for FRα (16, 17), effected superior tumor cell cytotoxicity and improved 
survival compared with IgG1 of equivalent specificity (18-21). Potential roles of 
monocytes/macrophages were suggested by loss of IgE-conferred survival advantage following 
monocyte depletion of human peripheral blood mononuclear cells (PBMCs) introduced with 
hMOv18 IgE (20). Monocyte-mediated tumor killing was demonstrated through both known IgE 
receptors: antibody-dependent cell-mediated cytotoxicity (ADCC) via the high affinity FcεRI, 
and phagocytosis (ADCP) via the low affinity FcεRII (CD23). Since inflammatory infiltrates of 
many tumors contain macrophages, re-polarizing these against cancer may constitute an 
important rationale for developing IgE cancer immunotherapy (22). To-date however, the 
capacity of IgE to recruit macrophages against cancer in an immunocompetent tumor-bearing 
setting has not been demonstrated and the mechanisms by which IgE may activate these cells 
against cancer remain unclear. IgE can rapidly mediate parasite neutralization by FcεR-
expressing cells including human macrophages (23, 24). Although TNFα, IL-10 and nitric oxide 
(NO) have been individually reported in these processes (23-25), the mechanisms engendered 
through cross-talk between immune cells, IgE antibodies and target cell antigens, including 
parasite or tumor antigens, have not been elucidated. 
Lack of cross-reactivity of human IgE with murine FcεRs and absence of trimeric FcεRI on 
murine monocytes/macrophages, eosinophils and other subsets have provided challenges for the 
design of immunologically-relevant models with which to study IgE class antibody functions. 
Previous immunodeficient mouse models, some reconstituted with human immune cells to 
provide IgE effector cells, were limited by short lifespans of human effector cells and incomplete 
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representation of human immunity. Additionally, certain human effector cell-secreted cytokines 
may not interact with the murine immune system.  
We investigated whether MOv18 IgE can inhibit tumor progression by recruiting and polarizing 
macrophages. We constructed a syngeneic rat model of FRα-expressing adenocarcinoma 
designed to better recapitulate the human IgE-Fcε receptor system and the patient setting. In this 
model, immune cells are found in their natural anatomical locations, immune cell FcεRI 
expression and distribution in rats mirrors that of humans, and rat effector cells (e.g. 
monocytes/macrophages) express trimeric FcεRI (αγ2) (26). We generated anti-FRα IgE and 
IgG with rat Fc sequences (rMOv18 IgE/IgG2b) to examine alongside antibodies with human Fc 
(hMOv18 IgE/IgG1). We assessed antibody efficacy and IgE-mediated tissue macrophage 
migration and activation in vivo, and TNFα and MCP-1 in tumor environments. We evaluated 
relevance in the human system and dissected the conditions that promote TNFα and MCP-1, by 
IgE-mediated human monocyte activation. Our findings support the superior therapeutic efficacy 
of IgE over IgG, and identify a previously-unappreciated tumor antigen-specific IgE-potentiated 
axis that promotes effector cell polarization and recruitment towards tumor cells. 
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 Materials and Methods 
 
Human Samples and Ethics  
Blood and tumor specimens were collected from 6 ovarian carcinoma patients (Supplementary 
Table S1) and blood drawn from 13 healthy volunteers (Supplementary Table S2), with informed 
written consent, in accordance with the Helsinki Declaration. Study design was approved by the 
Guy’s Research Ethics Committee, Guy’s and St. Thomas’ NHS Foundation Trust. 
 
Cell Lines 
The CC531tFR cell line, originally derived from a 1,2 dimethyhydrazine (DMH)-induced colon 
adenocarcinoma of a WAG-Rij rat (27) (Cell Lines Service), was transfected to express human 
FRα as previously-described, and selected on the basis of Geneticin resistance (S. Canevari, M. 
Colnaghi, Instituto Nazionale Tumori, Milan) (28, 29). IGROV1 human ovarian carcinoma cells 
naturally over-express human FRα (18, 30). A375 (human metastatic melanoma; CRL-11147), 
SKOV3 (human epithelial ovarian carcinoma, HTB-77), TOV21G (human ovarian clear cell 
carcinoma, CRL-11730), SKBR3 (human breast carcinoma HTB-30), U937 (human monocytic 
CRL-1593.2), and THP-1 (human monocytic; TIB 202) cells were from ATCC. FreeStyleTM 
293-F cells (R790-07) were from Invitrogen (Supplementary Materials and Methods). Cell lines 
from ATCC were authenticated by short tandem repeat profiling. Routine Mycoplasma testing 
was performed by PCR regularly on all cell lines. 
 
Production of anti-FRα antibodies with human and rat Fc regions 
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Chimeric mouse/human antibodies MOv18 IgE and IgG1 recognizing human FRα were 
engineered as before (18). Chimeric mouse/rat MOv18 IgE and IgG2b antibodies were designed 
with rat constant and mouse variable domains specific for human FRα (Supplementary Materials 
and Methods). 
 
Tumor cell cytotoxicity and phagocytosis (ADCC/ADCP) assays 
Antibody-dependent cell-mediated killing of FRα-expressing tumor cells was quantified by 
adapting a previously-described flow cytometric method (Supplementary Materials and 
Methods). 
 
Assessments of antibodies in vivo 
Immunocompetent syngeneic WAG rat model of FRα-expressing lung metastases 
Female Wistar Albino Glaxo (WAG/RijCrl) rats (Charles River) were maintained and handled in 
accordance with the Institutional Committees on Animal Welfare of the UK Home Office (The 
Home Office Animals Scientific Procedures Act, 1986). Rats were injected i.v. with 4x106 
CC531tFR tumor cells and subsequently treated with MOv18 antibodies (days 1 and 14 or 1, 7, 
14 and 21). Lung tumor burden was determined 26 days following CC531tFR inoculation by: 
mean number of surface-visible metastases/cm2; and % tumor occupancy [total white surface 
area (mm2) / total lung (black + white) surface area (mm2)]. 
Assessment of hMOv18 IgE in immune deficient mouse models 
Patient-derived intraperitoneal (i.p.) human ovarian carcinoma xenografts in female nu/nu mice 
were previously described (19). Subcutaneous IGROV1 tumors were established in C.B-17 
scid/scid (SCID) mice as before (18) (Supplementary Materials and Methods).  
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Isolation of rat effector cells from peripheral blood and lungs 
Rat primary monocytes were prepared from rat peripheral blood leukocytes (PBL) by flow 
cytometry cell sorting using a PE-conjugated antibody against CD172 (BD Biosciences) 
(Supplementary Materials and Methods).  
 
Flow cytometric evaluations of freshly-isolated tumor-infiltrating macrophages  
Phenotypic analysis of tumor-infiltrating macrophages from single cell suspensions of tumor-
bearing rat lungs was performed with directly-labeled monoclonal antibodies (Supplementary 
Materials and Methods).  
 
Criteria for evaluating immune cell infiltration of tumors 
H&E-stained sections were used to determine the tumor immune cellular infiltrate as a 
proportion of total tumor areas (Supplementary Materials and Methods). The percentage of 
tumor occupied by immune cells in each section was derived as follows: % immune cell 
occupancy = total area occupied by immune cells/total tumor area (Supplementary Fig. S1A). 
 
Evaluations of macrophage infiltration into tumors 
Sections double-stained for FRα (AF488, green) and CD68 (AF555, red) were used to determine 
ratios of within-tumor:peripheral CD68+ cells/mm2. CD68+ cells and the area covered by tumor 
(defined by tissue morphology, density of DAPI staining and FRα staining; Supplementary Fig. 
S1B) and periphery was calculated. (Supplementary Materials and Methods). 
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Quantitative real-time-PCR analysis of TNFα and MCP-1 expression by tumor cells and 
monocytes 
Cells harvested from ADCC and ex vivo stimulation assays were studied for MCP-1 and TNFα 
relative gene expression. Cells from ADCC assays were CD89-PE- and FRα-FITC-labeled and 
sorted using a FACSAria II Cell Sorter (BD Biosciences). Sorted cells and cells from ex vivo 
stimulation experiments (Supplementary Materials and Methods) were re-suspended in RLT 
buffer for RNA isolation by RNeasy Kit (Qiagen).  
 
Chemotaxis assay 
To analyze the chemotactic properties of MCP-1 on THP-1 cells and human primary monocytes, 
a chemotaxis assay was performed using Transwell® plates with a polycarbonate membrane 
insert and 5μm pore size (Costar®) (Supplementary Materials and Methods).  
 
Statistical methods and analyses of publically-available databases 
All statistical analyses (Supplementary Materials and Methods) were performed using 
GraphPadTM Prism software (version 5.03, GraphPadTM). P values are represented as follows: 
*=P<0.05, **=P<0.01, ***=P<0.001, ****=P<0.0001. Error bars represent SD and SEM in in 
vitro figures, and in in vivo figures and histological analyses, respectively. Clinical associations 
of tumor gene expression were assessed using publicly-available data (31), in Kaplan-Meier 
Plotter (http:/kmplot.com/analysis/) (Supplementary Materials and Methods). 
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Results 
 
Rat and human IgE and IgG display comparable in vitro properties 
We generated surrogate rMOv18 IgE and IgG2b antibodies (equivalent to mouse IgG2a/b and 
human IgG1, based on their complement-fixing and ADCC functions) recognizing human FRα 
in order to construct a syngeneic rat model system. Human FRα-expressing WAG rat syngeneic 
adenocarcinoma CC531tFR cells served as targets. Rat peripheral blood monocytes (CD172+) 
expressed FcεRI and bound rMOv18 IgE (Figs. 1A-B). rMOv18 IgE bound to rat FcεRI (αβγ2)-
expressing rat RBL-2H3 mast cells. rMOv18 IgG2b bound primary rat monocytes (expressing 
FcγRI), and RBL-2H3 cells (expressing low levels of rFcγRII/FcγRIII). Rat IgE and IgG2b 
bound to CC531tFR but not to FRα-negative A375 melanoma cells (Fig. 1B).  
Rat primary monocytes activated ex vivo with rMOv18 IgE, and rMOv18 IgG2b induced 
significant CC531tFR cell death compared with isotype control antibodies and equivalent to 
levels of IGROV1 ovarian tumor cell death triggered by human antibodies (Fig. 1C). 
Furthermore, monocytic cells stimulated with IL-4 to express the low affinity IgE receptor 
CD23/FcεRII, and primed with rMOv18 IgE, triggered significant CC531tFR death by ADCP 
over control antibody, equivalent to levels of ADCP triggered by hMOv18 IgE (Fig. 1D).  
This suggests that rMOv18 antibodies are functionally analogous to their human counterparts, at 
least with regard to binding FcεR+ and FRα+ cells, and their potentiation of particular effector 
functions.  
 
Anti-tumor activities of rat MOv18 IgE and IgG2b in vivo  
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We next examined the in vivo functions of rMOv18 IgE and IgG2b in an immunocompetent rat 
model of FRα+ CC531tFR lung metastases, designed to better recapitulate the spectrum and 
functions of human IgE effector cells and the patient setting (Supplementary Fig. S2).  
Immunofluorescent staining confirmed in situ FRα+ CC531tFR metastases (Fig. 2A). Dose-
dependent inhibition of tumors between 5mg/kg, 10mg/kg and 50mg/kg doses (% tumor 
occupancy of lungs) was observed with rMOv18 IgE (biweekly) (Fig. 2B). Lung metastases and 
tumor occupancy were significantly lower with rMOv18 IgE compared with rMOv18 IgG2b 
(P<0.0001) or PBS (P<0.0001) (Figs. 2C-E) at 10mg/kg doses. IgE and IgG2b significantly 
reduced lung metastases at 5mg/kg compared with PBS (P<0.0001). Given the longer serum 
half-life of IgG (14-25 days) compared with IgE (1-2 days) (32), we investigated whether dosing 
frequency could influence efficacy. rMOv18 IgE dosed weekly induced significantly-reduced 
tumor occupancy at doses as low as 1mg/kg compared with PBS (P<0.0001), with a dose-
dependent response between 3mg/kg, 10mg/kg (P=0.0002) and 50mg/kg (P<0.001) (Fig. 2F). 
Weekly 3mg/kg rMOv18 IgE afforded significantly (P=0.04) superior tumor growth restriction 
compared with IgG2b (Fig. 2G).  
Therefore, rMOv18 IgE and IgG2b were functionally active in vivo. Rat MOv18 IgE at 3mg/kg 
weekly and 10mg/kg biweekly doses effected superior tumor growth restriction compared with 
IgG2b. 
 
MOv18 IgE treatment is associated with rat macrophage infiltration into tumors   
We next investigated spontaneous, endogenous macrophage infiltration into tumors in 
immunocompetent rats. Histological evaluation of rat lungs showed reduced tumor islet density 
and increased glandular organization in rMOv18 IgE- compared with rMOv18 IgG2b-treated 
cohorts (Fig. 3A). Tumor areas occupied by immune and stromal cell infiltration were 
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significantly greater with rMOv18 IgE compared to PBS (P<0.0001) (Fig. 3B). We observed 
superior rat macrophage infiltration into tumors of rMOv18 IgE-treated rats. CD68+ macrophage 
clusters (red) surrounded sparse FRα+ (green) tumor islets. Macrophage density within tumor 
islets was higher in rMOv18 IgE- and rMOv18 IgG2b-treated rats compared with PBS (P=0.007) 
(Fig. 3C). CD68+ cell ratios within tumor islets:tumor periphery were significantly higher with 
rMOv18 IgE (rMOv18 IgG2b, P=0.03; PBS, P=0.003) (Fig. 3C, Supplementary Fig. S1). 
Additionally the intensity of macrophage infiltration correlated inversely with tumor occupancy 
in animals treated with rMOv18 IgE, and rMOv18 IgG2b but not PBS (Fig. 3D). Analyses of 
patient-derived ovarian carcinoma xenografts, where hMOv18 IgE introduced with human 
PBMCs prolonged survival of tumor-challenged mice compared to controls, showed that human 
CD68+ macrophage infiltration into tumors correlated with prolonged survival of hMOv18 IgE-
treated mice (r=0.67, P=0.009) (Fig. 3E) (19). Furthermore, in a subcutaneous IGROV1 human 
ovarian cancer xenograft in immunodeficient mice, significant tumor growth was observed in 
mice given PBS (P=0.0054), hMOv18 IgE alone (P=0.049) or human monocyte-enriched 
PBMCs (P=0.0014), but tumor growth was restricted in mice given hMOv18 IgE plus monocyte-
enriched cells (Fig. 3F). These findings suggest that the anti-tumor effects of MOv18 IgE in vivo, 
at least partly reflect immune effector functions of the antibody and enhanced macrophage influx 
into the tumor mass. 
 
Macrophage polarization and elevated TNFα, MCP-1 and IL-10 in lungs of IgE-treated 
rats 
Since antibody treatments were associated with enhanced macrophage infiltration into tumors, 
we investigated whether IgE was associated with polarization or maturation of tissue-resident 
macrophages. Consistent with immunohistochemical evaluations (Fig. 3), the mean percentages 
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of freshly-isolated lung CD68+ macrophages within the total CD45+ leukocyte populations 
(Supplementary Fig. S3) were elevated in rats treated with rMOv18 IgE compared with IgG2b 
and PBS (Fig. 4A). Macrophages from rMOv18 IgE-treated rats demonstrated enhanced 
expression of the co-stimulatory molecule CD80, compared with those from rMOv18 IgG2b- or 
PBS-treated animals (P=0.01). No differences in the alternatively activated (M2) scavenger 
receptor CD163 (33) expression were found between treatment groups (Figs. 4B-C).  
A higher proportion of CD68+ macrophages from rMOv18 IgE-treated rats expressed 
intracellular TNFα, compared with rMOv18 IgG2b- and PBS-treated cohorts (P=0.04) (Figs. 4B-
C). Additionally, a higher proportion of these cells also expressed intracellular IL-10 with 
rMOv18 IgE treatment, compared with rMOv18 IgG2b- (P=0.04) and PBS-treated cohorts 
(P=0.04). A proportion of macrophages from rMOv18 IgE-treated rats simultaneously expressed 
TNFα and IL-10 (Fig. 4D). In conjunction (Figs. 4E-F), we found significantly elevated TNFα, 
MCP-1 and IL-10 secreted in bronchoalveolar lavage (BAL) fluids of IgE-treated rats compared 
with IgG (IL-10, P=0.044; TNFα, P=0.017; MCP-1, P<0.001). Levels of IFN-γ, IL-1α, IL-1β, 
IL-2, IL-4, IL-5, IL-6, IL-8, and IL-12 did not differ significantly between treatment groups (Fig. 
4E). 
These data demonstrate TNFα-expressing mature macrophage subsets in rMOv18 IgE-treated rat 
lungs, along with a significantly-elevated secreted TNFα/MCP-1/IL-10 IgE-associated BAL 
profile.  
 
Cross-linking of cell surface-bound IgE triggers elevated TNFα by monocytes, and TNFα 
stimulates MCP-1 by monocytes and tumor cells 
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We sought to determine whether rMOv18 IgE treatment-associated macrophage activation is 
relevant in a human setting, and gain insights into how tumor antigen-specific IgE may trigger 
effector cell activation. Cross-linking of IgE antibodies of different antigen specificities (anti-
FRα MOv18, anti-hapten NIP IgE, anti-HER2 against the breast cancer tumor antigen HER2/neu 
and CSPG4 IgE, recognizing the melanoma tumor associated antigen Chondroitin Sulfate 
Proteoglycan 4 (34, 35)) on monocytes with polyclonal anti-IgE antibody (to mimic engagement 
by TAA-expressing tumor cells) significantly increased production of mRNA encoding TNFα by 
human monocytes, compared to IgE alone. Crosslinking of equivalent IgG1s did not trigger 
TNFα, nor did cross-linking of IgEs on human ovarian IGROV1 tumor cells (Fig. 5A).  
We then investigated whether IgE Fc-mediated TNFα upregulation can promote MCP-1 
secretion and therefore, putatively, monocyte mobilization. TNFα stimulation of human 
monocytic U937 cells and primary human monocytes triggered elevated MCP-1 mRNA 
expression compared with unstimulated cells (Fig. 5B left; P<0.0001), along with elevated MCP-
1 protein secretion compared with unstimulated cells (Fig. 5B right; U937 P=0.002; primary 
human monocytes P=0.0116).  
Stimulation of ovarian IGROV1, SKOV3 and TOV21G, breast SKBR3 and melanoma A375 
cancer cells with TNFα induced significantly-elevated MCP-1 mRNA expression and secretion 
compared with unstimulated cells (Fig. 5C). Furthermore, MCP-1 stimulation could effect 
human monocyte chemotaxis (human primary monocytes, THP-1 monocytes) in a concentration-
dependent manner (Fig. 5D).  
Therefore, TNFα upregulation, triggered by cross-linking of receptor-bound IgE, but not IgG, on 
the surface of monocytes, may induce MCP-1 production by human monocytes and a range of 
tumor cell types, putatively promoting further monocyte chemotaxis and potential accumulation 
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in tumors. These data suggest that IgE-mediated monocyte activation and TNFα upregulation 
may be relevant in the human setting. 
 
TNFα and MCP-1 are involved in antigen-specific IgE effector functions and may be 
associated with better patient survival  
We investigated whether TNFα/MCP-1 upregulation could be triggered by specific tumor 
antigen recognition and tumor cell cytotoxicity by IgE in vitro. Human monocytes with hMOv18 
IgE induced significantly-elevated IGROV1 cell ADCC compared with non-specific NIP IgE 
controls (Fig. 6A). hMOv18 IgE treatment was associated with significantly-elevated expression 
(relative to control IgE) of the same mediators found in lung extracts of IgE-treated rats in vivo 
(MCP-1, P=0.002; TNFα, P=0.019; IL-10, P=0.025), confirming their importance in IgE 
stimulation (Fig. 6B).  
In ADCC assays, MCP-1 secretion with hMOv18 IgE was significantly reduced (P=0.004) by 
TNFα receptor-blocking antibodies (Fig. 6C), and tumor-specific hMOv18 IgE, but not the non-
specific anti-NIP IgE, triggered upregulated MCP-1 mRNA expression by IGROV1 tumor cells. 
This effect was abrogated when TNFα signaling was blocked prior to stimulation with antibody 
(P=0.032; Fig. 6D). Therefore, MCP-1 production in the context of tumor antigen-specific IgE 
cytotoxicity is TNFα-dependent. 
To gain insights into a potential clinical relevance of the TNFα/MCP-1 axis, we interrogated 
publicly-available ovarian carcinoma gene expression datasets (Fig. 6E). We found significant 
associations of improved 5-year overall survival with elevated levels of our herein reported IgE-
mediated immune signatures (TNFα/MCP-1, P=0.016; TNFα/MCP-1/IL-10, P=0.022). These 
signatures were still associated with better overall survival alongside the macrophage marker 
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CD68 (P=0.04) and with the high- and low-affinity IgE Fc receptors (FcεRI, P=0.041; 
FcεRII/CD23, P=0.035). These findings may suggest that, if enhanced, the TNFα/MCP-1 axis 
may provide a responsive immune signature with protective potential. 
In summary, within tumors, cross-linking of MOv18 IgE on macrophages by FRα-expressing 
tumor cells induces macrophage TNFα upregulation. TNFα promotes elevated MCP-1 
production by both tumor cells and macrophages, putatively acting as a potent chemoattractant, 
drawing macrophages into tumors. Enhanced tumor cell-macrophage interactions further 
stimulate production of TNFα and thus MCP-1, forming a self-enhancing circuit of macrophage 
influx into MOv18 IgE-treated tumors (Fig. 6F). This supports a link between TNFα stimulation 
and MCP-1 expression in response to effector cell engagement and IgE cytotoxic functions 
against cancer. 
 
MOv18 IgE triggers anti-tumor ADCC by ovarian cancer patient effector cells 
We evaluated the capacity of hMOv18 IgE to trigger anti-tumor ADCC by activating human 
immune effector cells from patients with ovarian carcinomas. PBMCs from patients with FRα-
positive, FRα–negative and FRα–status unknown ovarian carcinomas (by 
immunohistochemistry, Fig. 7A), together with hMOv18 IgE, induced significantly-elevated 
ovarian carcinoma IGROV1 ADCC compared with non-specific NIP IgE-treated cells (Fig. 7B), 
and equivalent to that mediated by healthy volunteer PBMCs (Fig. 7C). Additionally, hMOv18 
IgE mediated anti-tumor ADCC against 3 FRα-expressing tumor cell lines (human ovarian 
carcinoma IGROV1 and SKOV3, and rat colon adenocarcinoma CC531tFR), but minimum 
ADCC against FRα-dim and FRα-negative cancer cell lines (human ovarian carcinoma 
TOV21G, and human breast carcinoma SKBR3 respectively, Fig. 7D, Supplementary Fig. S4). 
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Therefore, IgE-engendered anti-tumor functions are target antigen-specific, and have potential 
application with patient immune effector cells and against different target-expressing tumor cells.  
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Discussion 
 
We report the superior anti-tumor efficacy of TAA-specific IgE in an immunocompetent 
syngeneic rat model of cancer, uniquely suitable for the study of IgE anti-tumor effector 
functions. We furthermore describe a previously-unappreciated putative contribution of a 
TNFα/MCP-1 cascade to monocyte and macrophage repolarization and recruitment, delineated 
in the human IgE and human effector and tumor cell functional context. 
The functional significance of this IgE-induced TNFα/MCP-1 axis is supported by: a) enhanced 
intra-tumor infiltration by macrophages following IgE treatments; b) a TNFα-expressing lung 
macrophage compartment, and elevated TNFα and MCP-1 concentrations in BAL from IgE- but 
not IgG-treated rats; c) macrophage recruitment correlating with tumor growth restriction in IgE-
treated syngeneic rat and human xenograft mouse models of cancer; d) the ability of human IgE 
to trigger monocytes to upregulate TNFα in a class-specific manner; e) the induction of MCP-1 
production by TNFα in monocytes and tumor cells, in turn shown to promote a monocyte 
chemotactic response, f) the involvement of TNFα/MCP-1 in antigen-specific human IgE tumor 
ADCC, abrogated with TNFα receptor-specific blockade on monocyte effector cells and, g) 
publicly-available ovarian carcinoma gene expression datasets indicating associations between 
elevated levels of TNFα/MCP-1 with better survival. These findings reveal an immune cascade 
through which TAA-specific IgE may focus macrophages towards tumor cells.  
Rat and human MOv18 IgE showed comparable monocyte-mediated tumor cell killing. In 
immunocompetent rats, rMOv18 IgE demonstrated potential to compete favorably with IgG in a 
metastatic setting, and to restrict tumors in highly-vascularized organs like the lung, where IgG 
(based on its long half-life in the circulation) would have a major advantage. Rat and human 
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MOv18 IgE treatment-associated macrophage infiltration into tumors correlated with tumor 
growth restriction and better efficacy in the immunocompetent rat and human xenograft mouse 
models. This supports a function of recruiting macrophages towards tumor cells associated with 
IgE therapy in vivo. Stromal macrophages can express matrix-degrading, matrix–producing and 
pro-angiogenic factors (36), allowing regulation of stromal remodeling and neo-vascularization 
to support tumors. Conversely, macrophage density within tumor islets has been positively 
associated with patient survival (37, 38), and tumor islet-resident macrophages can express IL-
1α, IL-1β, IL-6, NOS and TNFα, the latter two thought to be involved in target cell–killing 
mechanisms of macrophages (39, 40). These mechanisms may fail to be effectively deployed 
against tumors, perhaps partly due to alternatively-polarized humoral immunity in cancers 
favoring antibody isotypes that fail to activate key effector cells such as macrophages (41-45). 
Here we show that tissue-resident macrophage subsets in IgE-treated cohorts are polarized to 
express the macrophage maturation and co-stimulatory marker CD80, as well as higher levels of 
pro-inflammatory TNFα. TNFα levels were also enhanced in BAL fluids of IgE-treated but not 
of IgG-treated rats. TNFα can also be expressed by activated macrophages known to act as 
effector cells in IgE-mediated parasite control (23-25). Our findings now directly link tumor-
immune cell interactions engendered by IgE with potentiating TNFα production, re-education 
and recruitment of monocytes and macrophages into tumors. These functions may be further 
explored in future studies that may include effector cell depletion or enrichment with different 
polarized phenotypes. Based on expression of TNFα, but not IL-4 in vitro and in vivo in the 
context of tumor antigen-specific IgE, our findings also suggest that macrophage activatory, but 
most likely not allergic, mechanisms might be employed by TAA-specific IgE to restrict the 
growth of tumor metastases. IL-4 has been shown to be a negative factor in IgE/FcεRI cross-
presentation by DCs and generation of cytotoxic T lymphocytes (12). It is therefore possible that 
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during Th2-type inflammation, IL-4 may prevent a TNFα/MCP-1 axis-driven macrophage 
response. 
The CC chemokine, M1 macrophage mediator and potent chemoattractant MCP-1 was also 
elevated in BAL fluid of rMOv18 IgE-treated rats. Cross-linking of macrophage-bound IgE by 
densely-expressed antigens on the surface of target cells, more likely to occur in tumor lesions, 
can trigger TNFα, which in turn may stimulate MCP-1. Our findings suggest that cross-linking 
on the monocyte surface by IgE, but not by IgG, may initiate this TNFα response. Monocytes 
and cancer cells respond to TNFα signals by producing MCP-1, consistent with increased 
recruitment of macrophages into tumors following rMOv18 IgE treatment. The high affinity of 
IgE for FcεRs on tissue-resident monocytes and macrophages may result in sustained antibody 
retention, thus favoring cross-linking of IgE by multivalent TAAs. This class-specific immune 
complex formation may potentiate TNFα production in tumor microenvironments and 
subsequent sustained in situ MCP-1 secretion by different cell subsets, providing an advantage 
for IgE immunotherapy against cancer. 
In human IgE, human monocyte and human tumor cell functional studies, TNFα stimulated 
tumor cells to upregulate MCP-1, which can trigger monocyte chemotaxis. We confirmed the 
relevance of both TNFα and MCP-1 in ADCC assays, where cross-linked IgE on the surface of 
human monocytes upregulated TNFα and MCP-1 production. Loss of MCP-1 production by 
tumor cells, and significant reduction in IgE-dependent tumor cell cytotoxicity when TNFα 
signaling was blocked, also suggest that MCP-1 upregulation and IgE anti-tumor functions 
require TNFα. We and others also demonstrate that tumor cells can be stimulated to produce 
MCP-1 (46-49). Additionally, potential synergistic effects between MCP-1 and IgE-mediated 
anti-tumor mechanisms were shown with an anti-MUC1 IgE antibody co-administered with 
MCP-1, to MUC1-expressing tumor-bearing hFcεRIα transgenic mice (50). Together, our 
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findings thus point to the putative involvement of a TNFα/MCP-1 cascade triggered by IgE-
mediated cross-talk between effector cells and tumor cells, and implicated in tumor cell growth 
restriction in vitro and in vivo. Conversely, we observed elevated levels of IL-10 in rMOv18 IgE-
treated rat lungs and in effector cell stimulation assays. In vitro infection of human macrophages 
with Toxoplasma gondii also upregulated IL-10, inversely correlating with iNOS and NO 
generation, and IL-10 was found to attenuate IgE-mediated parasite elimination by macrophages 
(25). IL-10 could therefore provide an in vivo mechanism for restricting IgE-induced effector cell 
activation, and requires further study. 
In summary, MOv18 IgE-potentiated tumor-restricting effects are superior to those of IgG in 
immunocompetent rats. IgE immune complex formation on monocytes and macrophages, 
initiated through cross-talk with TAA-expressing cancer cells, promotes effector cell 
polarization, activation and recruitment. This process is driven by TAA IgE-dependent TNFα 
and MCP-1 upregulation. Our findings draw parallels with physiological roles of IgE in anti-
parasitic immune surveillance but not in allergy. Engineering antibodies with Fc regions that 
confer unique effector cell-polarizing properties against cancer may open a new avenue for 
addressing tumor resistance to immune clearance. 
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Figure Legends 
  
Figure 1. Rat and human MOv18 antibodies display comparable effector functions. (A) 
Anti-rat FcεRI antibody or rMOv18 IgE bind to primary (CD172+) rat monocytes. (B) rMOv18 
IgE and IgG2b bind to rat primary monocytes, RBL-2H3 rat mast cells, FRα-expressing rat colon 
adenocarcinoma CC531tFR cells, and non-FRα-expressing human melanoma A375 cells (grey: 
non-specific isotype control or detection antibody control). (C) Quantification of ADCC against 
FRα-expressing tumor (rat CC531tFR and human ovarian carcinoma IGROV1) cells by rat or 
human MOv18 IgE- or IgG-primed primary monocytes. (D) Quantification of ADCC and ADCP 
against FRα-expressing CC531tFR tumor cells by rat or human MOv18 IgE-primed unstimulated 
(CD23-) or IL-4 stimulated (CD23+) monocytic cells, compared with non-specific antibody 
treatments or cells alone (n=3).  
 
Figure 2. Rat MOv18 IgE demonstrates superior tumor growth restriction. (A) FRα 
expression in vivo 26 days post-tumor challenge. Representative immunofluorescent microscopy 
images from lungs of tumor-bearing and healthy rats (n=5). (B) Percentage (%) tumor 
occupancy quantified following two biweekly (Q2W) doses of PBS (n=20), or 1 (n=3), 3 (n=2), 
5 (n=11), 10 (n=11) and 50 (n=2) mg/kg rMOv18 IgE. (C, E) Number of metastases/cm2 and % 
tumor occupancy quantified for PBS-treated rats (n=22) and rats treated with rMOv18 IgE 
(n=11) and IgG2b (n=11) at 10mg/kg and 5mg/kg Q2W. (D) Representative images of Indian 
ink-stained lungs from rMOv18 IgE-, IgG2b- (10mg/kg) and PBS-treated rats. (F) Percentage 
tumor occupancy quantified following weekly doses of rMOv18 IgE (n=10 per dose) or PBS 
(n=17) (mean of 1-3 independent experiments for B, C, E and F). (G) Number of metastases/cm2 
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and % tumor occupancy quantified for rats treated weekly with PBS or with rMOv18 IgE or 
IgG2b at 3mg/kg. 
 
Figure 3. MOv18 IgE treatment induces CD68+ macrophage infiltration into tumors. (A) 
Paraffin-embedded lung sections from PBS-, rMOv18 IgG-, and rMOv18 IgE-treated rats stained 
with H&E, and (B) percentages of immune cell infiltration into tumor foci quantified 
(demarcation strategy: Supplementary Fig. S1) (5 data points/animal, 5 animals/group). 
Magnification 200x. White arrow: glandular tumor islet; black arrow: immune and stromal cells.  
(C) Representative cryosections of lung from PBS-, rMOv18 IgG-, and rMOv18 IgE-treated rats 
co-stained with anti-human FRα (green) and anti-rat CD68 (red) antibodies. Intratumoral CD68+ 
cell density/mm2 (right panel, top) and ratio of tumour:peripheral CD68+ cells (right panel, 
bottom) were calculated. IgE (n=14), IgG (n=17), PBS (n=24). (D) Correlation of within-tumor 
CD68+ macrophage density with % tumor occupancy in rats treated with PBS (n=9), rMOv18 
IgE (n=13) and rMOv18 IgG2b (n=9). (E) Correlation of within-tumor CD68+ macrophage 
density with survival of nude mice with intraperitoneal human ovarian carcinoma xenografts, 
treated with human PBMC and hMOv18 IgE (n=13). (F) Inhibition of subcutaneous IGROV1 
tumor growth in SCID mice treated with PBS (n=4), hMOv18 IgE (n=4), monocyte-enriched 
effector cells (n=5), or monocyte-enriched effector cells plus hMOv18 IgE (n=5). 
 
Figure 4. Macrophages infiltrating tumors in IgE-treated rats are differentially-polarized. 
(A) Single cell suspensions, isolated from lungs of rats inoculated with CC531tFR tumor cells 26 
days previously, were stained with anti-CD45 and anti-CD68 antibodies. Infiltrating CD68+ 
macrophages were identified following successive gating on FSChiSSClow-hi and CD45+ 
populations (Supplementary Fig. S3) and the percentage of CD68+ cells in the CD45+ 
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populations calculated (right panel). (B, C) Percentages of lung CD68+ macrophages expressing 
CD80, CD163, TNFα and IL-10. (3 independent experiments for Figs. A-C). (D) Percentages of 
single- and double-positive (TNFα+/IL-10+) cells within the infiltrating CD68+ macrophage 
populations (n=3). (E) Cytokine/chemokine production measured in BAL fluid from tumor-
bearing rats given rMOv18 IgE, rMOv18 IgG2b, or PBS (n=3 per group). (F) For selected 
analytes, fold change values represent mean fluorescence intensity (MFI) for each replicate 
within the treatment (IgE or IgG) groups, divided by that of the PBS group. Results represent 2 
independent experiments.  
 
Figure 5. IgE cross-linked on monocytes triggers TNFα, which stimulates MCP-1. (A) 
Comparative real-time PCR analysis of TNFα expression by U937 monocytes (left) or FRα+ 
human ovarian carcinoma IGROV1 tumor cells (right) following cross-linking of human IgEs 
and IgGs of different antigen specificities by polyclonal antibodies for 1 hour (n=4). (B, C) 
Effects of TNFα, IL-4 and IL-10 (20ng/mL) stimulation on relative mRNA expression and 
secretion of MCP-1 by U937 monocytes (B; 10-hour stimulation), human primary monocytes (B; 
5-hour stimulation) and human ovarian carcinoma IGROV1, SKOV3 and TOV21G, human 
breast carcinoma SKBR3, and human melanoma A375 tumor cells (C; 10-hour stimulation). (D) 
Quantitation of human primary monocytes (top left) or THP-1 human monocytic cells, (bottom 
left) (representative images, right) migrating through a trans-well membrane in response to 
increasing MCP-1 concentrations (n=3).  
 
Figure 6. TNFα and MCP-1 are involved in IgE-mediated tumor killing and may be 
associated with better patient survival. (A) hMOv18 IgE effects significantly-elevated killing 
of human ovarian carcinoma IGROV1 cells by human U937 monocytes and primary monocytes 
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in vitro, compared with non-specific anti-NIP IgE controls (n=3). (B) Concentrations of 
cytokines/chemokines secreted in cultures of human primary monocytes incubated with IGROV1 
cells and hMOv18 IgE, control antibody NIP IgE or no antibody. (C) MCP-1 secreted in cultures 
of U937 monocytes incubated with IGROV1 cells and hMOv18 IgE was reduced when cells 
were incubated with blocking antibodies against the human TNFα receptors I and II prior to 
incubating with hMOv18 IgE (representative of two independent experiments). (D) MCP-1 
mRNA expression by IGROV1 cells was elevated following co-incubation with U937 
monocytes and hMOv18 IgE compared to controls (left), and reduced MCP-1 expression 
detected when IGROV1 cells were incubated with blocking antibodies against the human TNFα 
receptors I and II prior to treatment with hMOv18 IgE (right). (E) Kaplan-Meier curves showing 
higher TNFα/MCP-1, TNFα/MCP-1/IL-10, TNFα/MCP-1/IL-10+CD68, FcεRIα or CD23 
expression in 1582 ovarian cancers is significantly associated with improved 5-year overall 
survival. Ovarian tumor CD68 expression alone does not correlate with patient outcome. (F) 
Model summarizing a proposed mechanism of MOv18 IgE immunotherapy. (1) A TNFα/MCP-1 
axis promotes potent recruitment of further macrophages into tumors, (2) resulting in enhanced 
tumor cell-macrophage interactions and subsequent tumor cell death.  
 
Figure 7. MOv18 IgE triggers ADCC of different FRα-expressing tumor cell lines by 
human effector cells from patients with ovarian cancer  
(A) Paraffin-embedded sections of tumors from patients with ovarian cancer were stained to 
detect patients with FRα-positive (n=3) and FRα-negative (n=1) tumors. (B, C) ADCC/ADCP of 
FRα-expressing human ovarian carcinoma IGROV1 cells by hMOv18 IgE-primed PBMCs from 
patients (B) with FRα-positive (n=3), FRα-negative (n=1) and FRα-status unknown (n=2) tumors 
and from healthy volunteers (n=2) (C). (D) hMOv18 IgE effects significantly-elevated killing of 
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FRα-bright human ovarian carcinoma IGROV1 (n=3) and SKOV3 (n=3), and rat colon 
adenocarcinoma CC531tFR (n=2) tumor cells by monocytic cells, compared with non-specific 
anti-NIP IgE. Minimal killing of FRα-dim human ovarian carcinoma TOV21G (n=3) and human 
breast carcinoma SKBR3 (n=2) tumor cells by hMOv18 IgE was detected. 







